The IFI27 Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the TE1 human esophageal squamous cell carcinoma line, designed for loss-of-function studies of the interferon-inducible gene IFI27. This knockout model, produced via CRISPR/Cas9-mediated gene disruption, provides a heterogeneous cell pool that avoids clonal selection, enabling robust assessment of IFI27-dependent phenotypes in a cancerous epithelial background.
The TE1 cell line, originally derived from a human esophageal squamous cell carcinoma, serves as a widely utilized in vitro model for studying esophageal cancer biology. These cells retain characteristic features of esophageal epithelial malignancy, including active interferon signaling circuitry and intact apoptotic machinery, making them a relevant host for dissecting the roles of interferon-stimulated genes in tumorigenesis and therapy resistance.
IFI27 functions as an interferon-induced pro-apoptotic factor, transcriptionally activated by type I (IFN-??/??) and type II (IFN-??) interferons through the JAK-STAT pathway. Interferon binding to IFNAR1/IFNAR2 receptors triggers phosphorylation of JAK1 and TYK2 kinases, leading to STAT1/STAT2 activation and assembly of the ISGF3 complex with IRF9, which subsequently binds ISRE elements in the IFI27 promoter. The IFI27 protein promotes apoptosis by facilitating mitochondrial outer membrane permeabilization, potentially through interactions with BCL-2 family members, culminating in BAX/BAK activation, cytochrome c release, and caspase cascade execution. Additionally, IFI27 interacts with ISG15 and IFITM proteins, positioning it at the intersection of antiviral immunity and cell death pathways.
In the TE1 esophageal squamous cell carcinoma context, IFI27 knockout enables precise dissection of its contribution to malignant phenotypes, as esophageal cancers frequently exhibit dysregulated apoptosis and altered interferon responsiveness. By eliminating IFI27 expression in this cell line, researchers can investigate how loss of this pro-apoptotic factor affects tumor cell survival, proliferation, and sensitivity to interferon-based therapies or conventional chemotherapeutics. The polyclonal nature of the knockout pool minimizes clonal bias and better reflects the heterogeneity of editing outcomes, providing a more representative model for functional studies.
This knockout model is well-suited for a range of experimental applications, including Western blotting and RT-qPCR for confirming gene disruption and downstream target modulation, Annexin V and caspase activity assays to quantify apoptotic responses, flow cytometric analysis of cell cycle distribution, and RNA-seq for transcriptome-wide profiling of interferon-driven gene expression programs. Furthermore, it supports drug sensitivity screens to evaluate the role of IFI27 in modulating therapeutic responses in esophageal cancer cells, offering a versatile tool for both basic and translational research. For further information, please contact Ascent Research.
